Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPM.L Regulatory News (MPM)

  • There is currently no data for MPM

EPT Disclosure

25 Jan 2010 17:51

RNS Number : 0989G
Nomura Code Securities Limited
25 January 2010
 



 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS 

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Nomura Code Securities Limited

Company dealt in

Minster Pharmaceuticals Ltd

Class of relevant security to which the dealings being disclosed relate (Note 1)

Ordinary 5p shares - ISIN:GB00B142W462

Date of dealing

25-Jan-2010

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

Interests and short positions (following dealing) in the class of relevant security 

dealt in (Note 2)

Long

Short

Number

(%)

Number )

(%)

(1) Relevant securities 

1,460,696

2.48

0

(2) Derivatives (other than options)

0

0

0

0

(3) Options and agreements to purchase/sell

0

0

0

0

Total

1,460,696

2.48

Interests and short positions in relevant securities of the company, other than the class 

dealt in (Note 2)

Class of relevant security:

Long

Short

Number

(%)

Number )

(%)

(1) Relevant securities 

0

0

0

0

(2) Derivatives (other than options)

0

0

0

0

(3) Options and agreements to purchase/sell

0

0

0

0

Total

0

0

0

0

Rights to subscribe (Note 2)

Class of relevant security:

Details

n/a

n/a

3. DEALINGS (Note 3)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 4)

Purchase

1,437,284

5.8p

Total Purchases:

1,437,284

Total Sales:

Nil

 

(b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

n/a

n/a

n/a

n/a

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 4) 

n/a

n/a

n/a

n/a

n/a

n/a

n/a

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 4)

n/a

n/a

n/a

(d) Other dealings (including new securities) (Note 3)

Nature of transaction (Note 7)

Details

Price per unit (if applicable) (Note 4)

n/a

n/a

n/a

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

Date of disclosure

26-Jan-2010

Contact name

Niall Campbell

Telephone number

020 7776 1226

Name of offeree with which connected

Minster Pharmaceuticals plc

Nature of connection (Note 9)

Nomad and Broker

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website 

at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMLLFEDLIIEFII
Date   Source Headline
11th Dec 20181:21 pmRNSHolding(s) in Company
5th Dec 201811:24 amRNSHoldings in Company - Replacement
5th Dec 20189:05 amRNSHolding(s) in Company
4th Dec 20183:58 pmRNSHolding(s) in Company
4th Dec 20183:57 pmRNSHolding(s) in Company
30th Nov 20187:00 amRNSNew Business Division Within Mporium
14th Nov 20187:00 amRNSFundraising
2nd Nov 20187:00 amRNSNew strategic partnership with BPC
29th Oct 201811:24 amRNSHolding(s) in Company
3rd Oct 20187:00 amRNSUpdate on IMPACT's Sports Syncing technology
12th Sep 20187:00 amRNSBlock Admission Six Monthly Return
30th Aug 201810:04 amRNSDirector dealing
30th Aug 20187:00 amRNSHalf-year Report
18th Jul 20187:00 amRNSNew agency agreement for IMPACT
3rd Jul 20187:00 amRNSChange of Nominated Adviser and Broker
20th Jun 20187:00 amRNSIMPACT technology used by Performics for Samsung
30th May 20188:00 amRNSGrant of options
21st May 20189:59 amRNSResult of AGM
10th May 20189:17 amRNSHolding(s) in Company
9th May 20188:47 amRNSAnnual Report and Accounts and Notice of AGM
25th Apr 20187:00 amRNSFull Year Results
16th Mar 201812:01 pmRNSBLOCK ADMISSION SIX MONTHLY RETURN
13th Mar 20189:00 amRNSAppointment of Chief Operating Officer
26th Feb 20187:00 amRNSDirector dealing
23rd Feb 20188:31 amRNSGrant of options
23rd Feb 20187:00 amRNSBoard Changes
15th Feb 201811:39 amRNSDirector dealing
5th Jan 20187:00 amRNSNew agency agreement for IMPACT
22nd Dec 20177:00 amRNSResult of Fundraising
20th Dec 201711:15 amRNSProposed Subscription
15th Dec 20177:00 amRNSNew agency agreement for IMPACT
5th Dec 20177:00 amRNSContract for Fast Web Media
28th Nov 20177:00 amRNSNew agency agreement for IMPACT
21st Nov 20177:00 amRNSNew Commercial Agreement for IMPACT
6th Nov 20178:40 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSAppointment of Chief Technology Officer
1st Nov 20174:20 pmRNSHolding(s) in Company
1st Nov 20173:41 pmRNSRelease from Lock-in Agreement
29th Sep 201710:20 amRNSTotal Voting Rights
15th Sep 201710:39 amRNSBLOCK ADMISSION SIX MONTHLY RETURN
8th Aug 20177:01 amRNSBoard Changes
8th Aug 20177:00 amRNSHalf-year Report
25th Jul 20179:00 amRNSNotice of Results
21st Jun 20178:00 amRNSIndustry award and commercial agreement
18th May 20171:45 pmRNSResult of AGM
4th May 20175:04 pmRNSDirector/PDMR Shareholding
24th Apr 20177:00 amRNSFull Year Results
21st Mar 20177:00 amRNSResults of Placing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.